Events & Presentations

Upcoming Events

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.

Date Title
Archived Events
Date Event Details
Feb 6, 2018
8:30 AM ET
Argos Announces Option Agreement for Anti-PD1 Checkpoint Inhibitors
Nov 13, 2017
8:30 AM ET
Argos Therapeutics, Inc. Third Quarter 2017 Financial Results Conference Call
Sep 20, 2017
4:30 PM ET
Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress
Sep 12, 2017
8:00 AM ET
ESMO 2017 Presentation
Sep 11, 2017
ASCO Post - Robert A. Figlin, MD, on RCC: Results From the ADAPT Trial - Please see below for additional information regarding the webcast

Robert A. Figlin, MD, Professor and Chairman, Division of Hematology and Oncology at Cedars Sinai Medical Center, and co-principal investigator of the ADAPT trial, discusses the most recent interim analysis of data from the ongoing Phase 3 ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of metastatic renal cell carcinoma (mRCC) in intermediate and poor risk patients that was presented on Sept 11, 2017 at the European Society for Medical Oncology (ESMO) 2017 Congress. At the time of the interim analysis in February 2017, the estimated median overall survival for the Rocapuldencel-T combination arm was 27.7 months compared to 32.4 months for the standard-of-care control arm.  42.7% of the 307 patients in the combination arm demonstrated an objective response by RECIST criteria, a secondary endpoint in the trial, as compared with 39.4% of the 155 patients in the control arm.  Additionally, an analysis of overall survival in the first third of patients enrolled in the study (n=154) showed the estimated median overall survival for the combination arm was 30.1 months compared to 22.2 months for the control arm. Finally, consistent with the mechanism of action of Rocapuldencel-T, a statistically significant correlation was observed between the increase from baseline in the number of Rocapuldencel-T-induced memory T cells and overall survival in patients for whom immune response data has been analyzed and who received at least seven doses of Rocapuldencel-T.

Note: In the video, Dr. Figlin refers to median overall survival at the time of the interim analysis for patients who are intermediate and poor risk.  The figures he mentions refer to the patients in the combination arm and the control arm, respectively, all of whom were either intermediate or poor risk.

Apr 18, 2017
4:30 PM ET
Argos Update Call
Feb 22, 2017
8:30 AM ET
Argos Therapeutics Conference Call
Nov 14, 2016
8:30 AM ET
Argos Therapeutics, Inc. Third Quarter 2016 Financial Results Conference Call
= add file to Briefcase

Stock Quote

- 0.08 (-27.59%)

Day High:

Day Low:


3:59 PM ET on Apr 26, 2018
Delayed at least 20 minutes.